Cafepharma Today

May 14 2025 - AbbVie pays ADARx $335M cash for next-gen siRNA options
AbbVie pays ADARx $335M cash for next-gen siRNA options
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Roche reports final overall survival outcomes from breast cancer treatment trial
GSK buys phase III–ready liver drug in potential $2B deal to play in MASH arena
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Alnylam Pharma To Cut 33% Of Jobs
NASDAQ.com
Thursday, January 19, 2012 - 6:47pm
tags:
Alnylam, layoffs
Gardasil vs. Cervarix: How are MDs vaccinating against HPV?
Fierce Pharma/Sermo
Thursday, January 19, 2012 - 12:07pm
tags:
HPV, Merck, Gardasil, Cervarix, vaccines, GSK
AZ chief: Emerging markets are tougher than you think
Fierce Pharma
Thursday, January 19, 2012 - 12:05pm
tags:
AstraZeneca, emerging markets, David Brennan, Pharma CEOs
J&J to pay $158 million to settle Risperdal case
Markewatch
Thursday, January 19, 2012 - 12:03pm
tags:
settlements, JNJ, Risperdal
Gilead's Viread new formulations approved by FDA for use by children with HIV
Yahoo/Fly on the Wall
Thursday, January 19, 2012 - 11:13am
tags:
Viread, Gilread, HIV, FDA
Biopharma Stocks To Watch This Week
Seeking Alpha
Thursday, January 19, 2012 - 11:12am
tags:
BioDelivery Sciences, Biovest International, Celldex, MannKind, NovaBay Pharmaceuticals, Keryx, ImmunoCellular, Cel-Sci, Dendreon, Generex, Human Genome Sciences
MannKind Is Simply Running Out Of Cash
Seeking Alpha
Thursday, January 19, 2012 - 11:09am
tags:
cash, MannKind
Apricus Biosciences' Promising Pipeline Points To A Bright Future
Seeking Alpha
Thursday, January 19, 2012 - 11:08am
tags:
Apricus Biosciences, erectile dysfunction, Vitaros, Pfizer, Abbott Laboratories
2 High-Flying Biotechs Face a New Hurdle
Motley Fool
Thursday, January 19, 2012 - 10:57am
tags:
Bayer, ONYX Pharmaceuticals, Aeterna Zentaris, regorafenib, Keryx
Forest Labs: This Company is Quickly Approaching the Patent Cliff
Motley Fool
Thursday, January 19, 2012 - 10:54am
tags:
Forest Labs, patents, patent cliff, Lexapro, Namenda
United Therapeutics: Look To This Biotech Stock For Healthy Growth
Seeking Alpha
Thursday, January 19, 2012 - 10:53am
tags:
United Therapeutics
Zalicus: Novartis Files 3 WIPO Patents; I Remain Bullish
Seeking Alpha
Thursday, January 19, 2012 - 10:48am
tags:
Novartis, Zalicus, WIPO, patents
Forbes Earnings Preview: Johnson & Johnson
Forbes
Thursday, January 19, 2012 - 10:39am
tags:
JNJ, earnings
Bristol, AstraZeneca Diabetes Drug Fails to Win FDA Backing
Bloomberg
Thursday, January 19, 2012 - 10:38am
tags:
AstraZeneca, FDA, Bristol-Myers Squibb, diabetes, Dapagliflozin
J&J Hid Risperdal Studies on Diabetes Risk From Regulators, Witness Says
Bloomberg
Thursday, January 19, 2012 - 10:37am
tags:
diabetes, JNJ, Risperdal
Roche’s Zelboraf for Melanoma Spurs Other Skin Cancer’s Growth, Study Says
Bloomberg
Wednesday, January 18, 2012 - 5:59pm
tags:
Roche, Zelboraf, melanoma, skin cancer
Bristol-Myers’s Hepatitis C Pills Clear Virus Without Interferon in Study
Bloomberg
Wednesday, January 18, 2012 - 5:57pm
tags:
Bristol-Myers Squibb, hepatitis C, interferon
What Johnson & Johnson Does With Its Cash
Motley Fool
Wednesday, January 18, 2012 - 3:36pm
tags:
cash, JNJ
Pfizer, PhRMA back SOPA amid online protests
Fierce Pharma
Wednesday, January 18, 2012 - 3:35pm
tags:
Pfizer, PhRMA, SOPA, drug counterfeiting
2 Large Cap Pharma Stocks To Look Into, 2 To Avoid
Seeking Alpha
Wednesday, January 18, 2012 - 3:33pm
tags:
Pfizer, Merck, Eli Lilly, Bristol-Myers Squibb

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline
The GLP-1 Saga Continues, And How
In the Pipeline
Defluorination is Happening Inside You Right Now
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.